Published in Clin Cancer Res on June 01, 2003
Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma (SA03) | NCT00901836
Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas (SA02) | NCT00881595
Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer (2011) 2.34
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics (2007) 1.71
Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br J Cancer (2013) 1.53
Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg (2007) 1.48
Links between mutant p53 and genomic instability. J Cell Biochem (2012) 1.41
Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene (2009) 1.34
Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol (2004) 1.26
Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Arch (2009) 1.19
Genetic aberrations of gastrointestinal stromal tumors. Cancer (2008) 1.18
The C-kit receptor-mediated signal transduction and tumor-related diseases. Int J Biol Sci (2013) 1.13
Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol (2006) 1.05
Animal models of soft-tissue sarcoma. Dis Model Mech (2010) 1.01
Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol (2010) 0.97
Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. Genome Biol (2013) 0.97
Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med (2009) 0.96
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol Cancer Ther (2013) 0.95
Does limb-salvage surgery offer patients better quality of life and functional capacity than amputation? Clin Orthop Relat Res (2012) 0.92
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget (2016) 0.91
Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. Sarcoma (2014) 0.88
Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma. Invest New Drugs (2014) 0.87
[Significance of molecular-cytogenetic findings in mucoepidermoid carcinoma as an example of salivary gland tumors]. Pathologe (2005) 0.87
Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Core Evid (2010) 0.87
Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med (2008) 0.86
Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry. Am J Surg Pathol (2011) 0.86
Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value. Histopathology (2015) 0.85
Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment. Chin J Cancer (2013) 0.84
PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells. Neoplasia (2008) 0.83
Shared cell surface marker expression in mesenchymal stem cells and adult sarcomas. Stem Cells Transl Med (2012) 0.83
Myogenic transcription factors regulate pro-metastatic miR-182. Oncogene (2015) 0.83
Abdominal soft tissue sarcoma: a multicenter retrospective study. Int J Clin Oncol (2010) 0.82
Therapeutic response in musculoskeletal soft tissue sarcomas: evaluation by MRI. NMR Biomed (2011) 0.81
Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. BMC Cancer (2015) 0.80
Cross-cultural adaptation and validation of the Chinese version of Toronto Extremity Salvage Score for patients with extremity sarcoma. Springerplus (2016) 0.79
Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182. Cancer Lett (2015) 0.79
Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma. Cancer Lett (2016) 0.78
Verticillin A Inhibits Leiomyosarcoma and Malignant Peripheral Nerve Sheath Tumor Growth via Induction of Apoptosis. Clin Exp Pharmacol (2016) 0.78
Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR. Mol Cancer Ther (2017) 0.77
PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications. Int J Exp Pathol (2009) 0.77
Methods to generate genetically engineered mouse models of soft tissue sarcoma. Methods Mol Biol (2015) 0.77
Correlations of telomere length, P53 mutation, and chromosomal translocation in soft tissue sarcomas. Int J Clin Exp Pathol (2015) 0.76
Molecular basis of differentiation therapy for soft tissue sarcomas. Trends Cancer Res (2016) 0.75
Targeting protein kinases to reverse multidrug resistance in sarcoma. Cancer Treat Rev (2015) 0.75
Epithelioid hemangioendotheliomas with TFE3 gene translocations are compossible with CAMTA1 gene rearrangements. Oncotarget (2016) 0.75
Impact of MDM2 309T>G polymorphism on sarcomagenesis. Int J Clin Exp Med (2015) 0.75
MicroRNA-16 suppresses metastasis in an orthotopic, but not autochthonous, mouse model of soft tissue sarcoma. Dis Model Mech (2015) 0.75
Occurrence of Comorbidities before and after Soft Tissue Sarcoma Diagnosis. Sarcoma (2012) 0.75
Heterogeneity in sarcoma cell lines reveals enhanced motility of tetraploid versus diploid cells. Oncotarget (2016) 0.75
Tumor resection at the pelvis using three-dimensional planning and patient-specific instruments: a case series. World J Surg Oncol (2016) 0.75
Stereotactic Radiosurgery for the Treatment of Primary and Metastatic Spinal Sarcomas. Technol Cancer Res Treat (2016) 0.75
A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging. PLoS One (2017) 0.75
[Molecular markers in salivary gland tumors: their use in diagnostic and prognostic workup]. Pathologe (2009) 0.75
Effect of intraoperative radiotherapy in the treatment of retroperitoneal sarcoma. Int J Clin Oncol (2017) 0.75
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol (2002) 20.87
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
High-resolution mapping and characterization of open chromatin across the genome. Cell (2008) 15.93
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet (2006) 6.67
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol (2007) 6.11
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
Clinicopathologic correlates of solitary fibrous tumors. Cancer (2002) 5.96
Biology of gastrointestinal stromal tumors. J Clin Oncol (2004) 5.89
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res (2006) 5.69
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood (2005) 5.58
Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol (2005) 5.53
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol (2005) 4.79
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol (2011) 4.77
Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med (2011) 4.68
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med (2006) 4.52
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol (2006) 4.50
Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol (2004) 4.46
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol (2010) 4.34
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg (2003) 4.25
Quality of complication reporting in the surgical literature. Ann Surg (2002) 4.21
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (2009) 4.21
Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn (2005) 4.21
BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res (2003) 4.17
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A (2005) 4.15
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg (2007) 4.09
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol (2010) 4.01
Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol (2007) 3.79
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol (2009) 3.72
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70